Gleevec Uses

Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia
HES and CEL are blood disorders in which the bone marrow makes too many eosinophils, a type of white blood cell. The large number of eosinophils can spill out of the blood into body tissues, where they can cause damage to organs such as the heart, liver, or spleen. Chronic eosinophilic leukemia can progress to acute leukemia.
 
Aggressive Systemic Mastocytosis
Systemic mastocytosis is a type of myeloproliferative disease in which a large amount of abnormally functioning mast cells are found in one or more organs, which can lead to organ failure. Mast cells are a type of immune system cell that releases chemicals (such as histamine) in response to inflammation and allergic reactions. Aggressive systemic mastocytosis is an aggressive, or more rapidly progressing, form of the disorder. Gleevec is approved to treat adults with ASM.
 

Using Gleevec for Dermatofibrosarcoma Protuberans

Dermatofibrosarcoma protuberans (DFSP) is a rare type of cancer that occurs in the dermis, or the second layer of the skin. DFSP can grow aggressively throughout the skin, causing large tender masses that may bleed. However, the cancer rarely spreads to other parts of the body.
 
DFSP may be treated with surgery. Because the cancer normally spreads so widely throughout the skin, however, it can be difficult to completely remove, and often comes back after surgery. Gleevec is approved to treat DFSP that cannot be treated with surgery, has returned after previous treatment, or has spread to other areas of the body (is metastatic).
 
The Zen of Cancer Caregiving - Recharge Your Batteries!

Gleevec Medication Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.